Curi Bio Closes $10M Series A Funding Round

Curi Bio

Curi Bio Inc., a Seattle, WA-based developer of human stem cell-based platforms for drug discovery, held the second closing of a $10m Series A financing.

New investors UTC Investment and DS Asset Management joined current investor and Series A lead Dynamk Capital.

The company intends to use the funds to scale its existing business and accelerate the development of its engineered tissue analysis platforms, including its Mantarray platform.

Led by Michael Cho, JD, CEO, Curi Bio provides a preclinical discovery platform that combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Its suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.

The core technologies and products include: 

  • NanoSurface Plates for structural maturation, 
  • Cytostretcher cell-stretching instruments, and
  • the Mantarray platform for contractility analysis.